

=> fil reg

FILE 'REGISTRY' ENTERED AT 15:53:00 ON 09 JUL 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 8 JUL 2002 HIGHEST RN 437701-77-4

DICTIONARY FILE UPDATES: 8 JUL 2002 HIGHEST RN 437701-77-4

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.


Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d sta que 19

L2 SCR 1992

L6 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 26

STEREO ATTRIBUTES: NONE

L8 116 SEA FILE=REGISTRY SSS FUL L2 AND L6

L9 14 SEA FILE=REGISTRY ABB=ON PLU=ON 4432.3.65/RID AND 46.150.18/R
ID AND L8

=> d his 19-

(FILE 'REGISTRY' ENTERED AT 15:44:48 ON 09 JUL 2002)

SAV L8 QAZI780/A

L9 14 S 4432.3.65/RID AND 46.150.18/RID AND L8

FILE 'HCAOLD' ENTERED AT 15:50:45 ON 09 JUL 2002

L10 0 S L9

FILE 'HCAPLUS' ENTERED AT 15:50:48 ON 09 JUL 2002

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov

L11 4 S L9
L12 4 S L11 AND (PETERS ? OR LIU ? OR JOHANSSON ? OR RYAN ? OR CHAO ?
L13 3 S L11 AND SRI?/PA,CS
L14 4 S L11-L13


FILE 'USPATFULL, USPAT2' ENTERED AT 15:52:38 ON 09 JUL 2002
L15 5 S L9

FILE 'REGISTRY' ENTERED AT 15:53:00 ON 09 JUL 2002

=> d ide can tot 19

L9 ANSWER 1 OF 14 REGISTRY COPYRIGHT 2002 ACS
RN 355861-40-4 REGISTRY
CN 19-Norpregna-1,3,5(10)-trien-3-ol, 7-methyl-21-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, (7.alpha.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C34 H47 N O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:232440

REFERENCE 2: 135:195698

L9 ANSWER 2 OF 14 REGISTRY COPYRIGHT 2002 ACS
RN 355861-39-1 REGISTRY
CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[2-(diethylamino)ethoxy]phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C33 H47 N O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:232440

REFERENCE 2: 135:195698

L9 ANSWER 3 OF 14 REGISTRY COPYRIGHT 2002 ACS

RN 354808-47-2 REGISTRY

CN Benzamide, N,N-diethyl-4-[[[(7.alpha.)-3-hydroxy-7-methyl-19-norpregna-1,3,5(10)-trien-21-yl]oxy]-3-methoxy-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN SR 16234

FS STEREOSEARCH

MF C33 H45 N O4 . C6 H8 O7

SR CA


LC STN Files: BIOSIS, CA, CAPLUS, DRUGNL, DRUGUPDATES, TOXCENTER, USPATFULL

CM 1

CRN 354808-46-1

CMF C33 H45 N O4


Absolute stereochemistry.



CM 2

CRN 77-92-9

CMF C6 H8 O7



1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:180905

L9 ANSWER 4 OF 14 REGISTRY COPYRIGHT 2002 ACS

RN 354808-46-1 REGISTRY

CN Benzamide, N,N-diethyl-4-[[[(7.alpha.)-3-hydroxy-7-methyl-19-norpregna-1,3,5(10)-trien-21-yl]oxy]-3-methoxy- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN SR 16233

FS STEREOSEARCH


MF C33 H45 N O4

CI COM

SR CA

LC STN Files: CA, CAPLUS, DRUGUPDATES, TOXCENTER, USPATFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:180905

L9 ANSWER 5 OF 14 REGISTRY COPYRIGHT 2002 ACS
RN 354758-98-8 REGISTRY
CN Benzamide, N,N-diethyl-3-methoxy-4-[[(7.alpha.)-7-methyl-3-
[(methylsulfonyl)oxy]-19-norpregna-1,3,5(10)-trien-21-yl]oxy]- (9CI) (CA
INDEX NAME)
FS STEREOSEARCH
MF C34 H47 N O6 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:180905

L9 ANSWER 6 OF 14 REGISTRY COPYRIGHT 2002 ACS
RN 354758-87-5 REGISTRY
CN Benzamide, N,N-diethyl-3-methoxy-4-[[3-(1-methylethoxy)-6-oxo-19-norpregna-1,3,5(10)-trien-21-yl]oxy]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C35 H47 N O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 135:180905

L9 ANSWER 7 OF 14 REGISTRY COPYRIGHT 2002 ACS
RN 354758-86-4 REGISTRY
CN Benzamide, N,N-diethyl-3-methoxy-4-[[(7.alpha.)-7-methyl-3-(1-methylethoxy)-6-oxo-19-norpregna-1,3,5(10)-trien-21-yl]oxy]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C36 H49 N O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


REFERENCE 1: 135:180905

L9 ANSWER 8 OF 14 REGISTRY COPYRIGHT 2002 ACS
RN 229634-98-4 REGISTRY
CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[(diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-, (7.alpha.)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C33 H47 N O3 . C6 H8 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 229634-97-3
CMF C33 H47 N O3


Absolute stereochemistry.



CM 2

CRN 77-92-9

CMF C6 H8 O7



3 REFERENCES IN FILE CA (1967 TO DATE)

3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:232440

REFERENCE 2: 135:195698

REFERENCE 3: 131:88084

L9 ANSWER 9 OF 14 REGISTRY COPYRIGHT 2002 ACS

RN 229634-97-3 REGISTRY

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[(diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C33 H47 N O3

CI COM

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:232440

REFERENCE 2: 135:195698

REFERENCE 3: 131:88084

L9 ANSWER 10 OF 14 REGISTRY COPYRIGHT 2002 ACS

RN 229634-96-2 REGISTRY

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[(dimethylamino)methyl]-2-methoxyphenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C31 H43 N O3

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.




3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 3: 131:88084

```
L9 ANSWER 11 OF 14 REGISTRY COPYRIGHT 2002 ACS
RN 229634-95-1 REGISTRY
CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[2-methoxy-4-(1-
pyrrolidinylmethyl)phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C33 H45 N O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
```

Absolute stereochemistry.




3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 3: 131:88084

```
L9 ANSWER 12 OF 14 REGISTRY COPYRIGHT 2002 ACS
RN 229634-94-0 REGISTRY
CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[2-methoxy-4-[(4-methyl-1-
piperazinyl)methyl]phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C34 H48 N2 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
```

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:232440

REFERENCE 2: 135:195698

REFERENCE 3: 131:88084

L9 ANSWER 13 OF 14 REGISTRY COPYRIGHT 2002 ACS

RN 229634-93-9 REGISTRY

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[3-methoxy-4-(1-piperidinylmethyl)phenoxy]-7-methyl-, (7.alpha.)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C34 H47 N O3 . C6 H8 O7

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 229634-92-8

CMF C34 H47 N O3


Absolute stereochemistry.



CM 2.

CRN 77-92-9

CMF C6 H8 O7



3 REFERENCES IN FILE CA (1967 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:232440

REFERENCE 2: 135:195698

REFERENCE 3: 131:88084

L9 ANSWER 14 OF 14 REGISTRY COPYRIGHT 2002 ACS

RN 229634-92-8 REGISTRY

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[3-methoxy-4-(1-piperidinylmethyl)phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C34 H47 N O3

CI COM

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:232440

REFERENCE 2: 135:195698

REFERENCE 3: 131:88084

=> fil uspatall

FILE 'USPATFULL' ENTERED AT 15:53:14 ON 09 JUL 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:53:14 ON 09 JUL 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> d l15 bib abs hitstr tot

L15 ANSWER 1 OF 5 USPATFULL

AN 2002:55018 USPATFULL

TI Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use

IN Tanabe, Masato, Palo Alto, CA, UNITED STATES

Peters, Richard H., San Jose, CA, UNITED STATES

Chao, Wan-Ru, Sunnyvale, CA, UNITED STATES

Jong, Ling, Sunnyvale, CA, UNITED STATES

PI US 2002032181 A1 20020314

AI US 2001-918890 A1 20010730 (9)

RLI Division of Ser. No. US 1998-220408, filed on 24 Dec 1998, GRANTED, Pat. No. US 6281205 Continuation-in-part of Ser. No. US 1997-998877, filed on 24 Dec 1997, GRANTED, Pat. No. US 6054446

DT Utility

FS APPLICATION

LREP REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025

CLMN Number of Claims: 41

ECL Exemplary Claim: 1

DRWN 3 Drawing Page(s)

LN.CNT 3381

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel anti-estrogenic compounds are provided which are useful to treat a variety of disorders, particularly estrogen-dependent disorders. Preferred compounds have a 1,3,5-estratriene nucleus, and are substituted at the C-17 or C-11 position with a molecular moiety which renders the compounds effective to competitively block the binding of estrogen to its receptor. Particularly preferred compounds are 17-desoxy-1,3,5-estratrienes. Therapeutic methods and pharmaceutical compositions are provided as well.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 229634-92-8P 229634-97-3P

(prepn. of novel antiestrogenic steroids)

RN 229634-92-8 USPATFULL

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[3-methoxy-4-(1-piperidinylmethyl)phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229634-97-3 USPATFULL

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[(diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 229634-93-9P 229634-94-0P 229634-95-1P

229634-96-2P 229634-98-4P

(prepn. of novel antiestrogenic steroids)

RN 229634-93-9 USPATFULL


CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[3-methoxy-4-(1-piperidinylmethyl)phenoxy]-7-methyl-, (7.alpha.)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 229634-92-8

CMF C34 H47 N O3


Absolute stereochemistry.



CM 2

CRN 77-92-9


CMF C6 H8 O7



RN 229634-94-0 USPATFULL

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[2-methoxy-4-[(4-methyl-1-piperazinyl)methyl]phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229634-95-1 USPATFULL

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[2-methoxy-4-(1-pyrrolidinylmethyl)phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229634-96-2 USPATFULL

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[(dimethylamino)methyl]-2-methoxyphenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 229634-98-4 USPATFULL


CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[(diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-, (7.alpha.)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 229634-97-3

CMF C33 H47 N O3


Absolute stereochemistry.



CM 2

CRN 77-92-9

CMF C6 H8 O7



L15 ANSWER 2 OF 5 USPATFULL

AN 2002:55017 USPATFULL

TI Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use

IN Tanabe, Masato, Palo Alto, CA, UNITED STATES
 Peters, Richard H., San Jose, CA, UNITED STATES
 Chao, Wan-Ru, Sunnyvale, CA, UNITED STATES
 Jong, Ling, Sunnyvale, CA, UNITED STATES

PI US 2002032180 A1 20020314

AI US 2001-872825 A1 20010531 (9)

RLI Continuation-in-part of Ser. No. US 1998-220408, filed on 24 Dec 1998, GRANTED, Pat. No. US 6281205 Continuation-in-part of Ser. No. US 1997-998877, filed on 24 Dec 1997, GRANTED, Pat. No. US 6054446

DT Utility

FS APPLICATION

LREP REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025

CLMN Number of Claims: 41

ECL Exemplary Claim: 1

DRWN 3 Drawing Page(s)

LN.CNT 3369

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel anti-estrogenic compounds are provided which are useful to treat a variety of disorders, particularly estrogen-dependent disorders. Preferred compounds have a 1,3,5-estratriene nucleus, and are substituted at the C-17 or C-11 position with a molecular moiety which renders the compounds effective to competitively block the binding of estrogen to its receptor. Particularly preferred compounds are 17-desoxy-1,3,5-estratrienes. Therapeutic methods and pharmaceutical compositions are provided as well.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT **229634-92-8P 229634-97-3P**

(prepn. of antiestrogenic steroids)

RN 229634-92-8 USPATFULL

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[3-methoxy-4-(1-piperidinylmethyl)phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229634-97-3 USPATFULL

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[(diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 229634-93-9P 229634-94-0P 229634-95-1P

229634-96-2P 229634-98-4P

(prepn. of antiestrogenic steroids)

RN 229634-93-9 USPATFULL


CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[3-methoxy-4-(1-piperidinylmethyl)phenoxy]-7-methyl-, (7.alpha.)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 229634-92-8

CMF C34 H47 N O3


Absolute stereochemistry.



CM 2

CRN 77-92-9


CMF C6 H8 O7



RN 229634-94-0 USPATFULL

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[2-methoxy-4-[(4-methyl-1-piperazinyl)methyl]phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229634-95-1 USPATFULL

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[2-methoxy-4-(1-pyrrolidinylmethyl)phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229634-96-2 USPATFULL

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[(dimethylamino)methyl]-2-methoxyphenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 229634-98-4 USPATFULL


CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[(diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-, (7.alpha.)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 229634-97-3

CMF C33 H47 N O3


Absolute stereochemistry.



CM 2

CRN 77-92-9

CMF C6 H8 O7




IT 355861-39-1P 355861-40-4P

(prepn. of antiestrogenic steroids)

RN 355861-39-1 USPATFULL

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[2-(diethylamino)ethoxy]phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 355861-40-4 USPATFULL

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 7-methyl-21-[4-[2-(1-


piperidinyl)ethoxy]phenoxy]-, (7.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 3 OF 5 USPATFULL
 AN 2001:200162 USPATFULL
 TI Synthesis of anti-estrogenic and other therapeutic steroids from
 21-hydroxy-19-norpregna-4-en-3-one
 IN Peters, Richard H., San Jose, CA, United States
 Liu, Jyanwei, Sunnyvale, CA, United States
 Johansson, John G., Menlo Park, CA, United States
 Ryan, Kenneth J., Sunnyvale, CA, United States
 Chao, Wan-Ru, Sunnyvale, CA, United States
 Tanabe, Masato, Palo Alto, CA, United States
 PI US 2001039269 A1 20011108
 AI US 2001-780990 A1 20010209 (9)
 PRAI US 2000-181738P 20000211 (60)
 DT Utility
 FS APPLICATION
 LREP REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
 CLMN Number of Claims: 44
 ECL Exemplary Claim: 1
 DRWN 23 Drawing Page(s)
 LN.CNT 1857
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Syntheses of steroids such as 3-hydroxy-7.alpha.-methyl-21-[2'-methoxy-4'-(diethylaminomethyl)-phenoxy]-19-norpregna-1,3,5(10)triene citrate ("SR 16234") and analogs thereof are provided, wherein 21-hydroxy-19-norpregna-4-en-3-one serves as a starting material or intermediate. The latter compound may be readily prepared from estrone-3-methyl ether. Certain intermediates in these syntheses also have value as therapeutic agents, for example in the treatment of prostate disorders such as prostatic cancer.
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 354808-46-1P, SR 16233
 (prepn. of antiestrogenic steroids)
 RN 354808-46-1 USPATFULL
 CN Benzamide, N,N-diethyl-4-[[[(7.alpha.)-3-hydroxy-7-methyl-19-norpregna-1,3,5(10)-trien-21-yl]oxy]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 354808-47-2P, SR 16234

(prepn. of antiestrogenic steroids)

RN 354808-47-2 USPATFULL


CN Benzamide, N,N-diethyl-4-[[(7.alpha.)-3-hydroxy-7-methyl-19-norpregna-1,3,5(10)-trien-21-yl]oxy]-3-methoxy-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 354808-46-1

CMF C33 H45 N O4


Absolute stereochemistry.



CM 2

CRN 77-92-9

CMF C6 H8 O7




IT 354758-86-4P 354758-87-5P 354758-98-8P
(prepn. of antiestrogenic steroids)

RN 354758-86-4 USPATFULL

CN Benzamide, N,N-diethyl-3-methoxy-4-[[(7.alpha.)-7-methyl-3-(1-methylethoxy)-6-oxo-19-norpregna-1,3,5(10)-trien-21-yl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354758-87-5 USPATFULL

CN Benzamide, N,N-diethyl-3-methoxy-4-[[3-(1-methylethoxy)-6-oxo-19-norpregna-1,3,5(10)-trien-21-yl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354758-98-8 USPATFULL

CN Benzamide, N,N-diethyl-3-methoxy-4-[[(7.alpha.)-7-methyl-3-
[(methylsulfonyl)oxy]-19-norpregna-1,3,5(10)-trien-21-yl]oxy]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 4 OF 5 USPATFULL

AN 2001:142341 USPATFULL

TI Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use

IN Tanabe, Masato, Palo Alto, CA, United States

Peters, Richard H., San Jose, CA, United States

Chao, Wan-Ru, Sunnyvale, CA, United States

Jong, Ling, Sunnyvale, CA, United States

PA SRI International, Menlo Park, CA, United States (U.S. corporation)

PI	US 6281205	B1	20010828
----	------------	----	----------

AI US 1998-220408 19981224 (9)
RLI Continuation-in-part of Ser. No. US 1997-998877, filed on 24 Dec 1997,
now patented, Pat. No. US 6054446, issued on 25 Apr 2000
DT Utility
FS GRANTED
EXNAM Primary Examiner: Badio, Barbara P.
LREP Reed, Dianne E. Reed & Associates
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 3164

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel anti-estrogenic compounds are provided which are useful to treat a variety of disorders, particularly estrogen-dependent disorders. Preferred compounds have a 1,3,5(10)-estratriene nucleus, and are substituted at the C-17 or C-11 position with a molecular moiety which renders the compounds effective to competitively block the binding of estrogen to its receptor. Particularly preferred compounds are 17-desoxy-1,3,5(10)-estratrienes. Therapeutic methods and pharmaceutical compositions are provided as well.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 229634-92-8P 229634-97-3P

(prepn. of antiestrogenic steroids)

RN 229634-92-8 USPATFULL

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[3-methoxy-4-(1-piperidinylmethyl)phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229634-97-3 USPATFULL

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[(diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 229634-93-9P 229634-94-0P 229634-95-1P
 229634-96-2P 229634-98-4P 355861-39-1P
 355861-40-4P

(prepn. of antiestrogenic steroids)

RN 229634-93-9 USPATFULL


CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[3-methoxy-4-(1-piperidinylmethyl)phenoxy]-7-methyl-, (7.alpha.)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 229634-92-8

CMF C34 H47 N O3


Absolute stereochemistry.



CM 2

CRN 77-92-9


CMF C6 H8 O7



RN 229634-94-0 USPATFULL

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[2-methoxy-4-[(4-methyl-1-piperazinyl)methyl]phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229634-95-1 USPATFULL

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[2-methoxy-4-(1-pyrrolidinylmethyl)phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229634-96-2 USPATFULL

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[(dimethylamino)methyl]-2-methoxyphenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 229634-98-4 USPATFULL
 CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[(diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-, (7.alpha.)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 229634-97-3
 CMF C33 H47 N O3

Absolute stereochemistry.



CM 2


CRN 77-92-9
 CMF C6 H8 O7



RN 355861-39-1 USPATFULL

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[2-(diethylamino)ethoxy]phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 355861-40-4 USPATFULL

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 7-methyl-21-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, (7.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 5 OF 5 USPATFULL

AN 2000:50696 USPATFULL

TI Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use

IN Tanabe, Masato, Palo Alto, CA, United States
 Peters, Richard H., San Jose, CA, United States
 Chao, Wan-Ru, Sunnyvale, CA, United States
 Jong, Ling, Sunnyvale, CA, United States
 PA SRI International, Menlo Park, CA, United States (U.S. corporation)
 PI US 6054446 20000425
 AI US 1997-998877 19971224 (8)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Badio, Barbara
 LREP Reed, Dianne E. Reed & Associates
 CLMN Number of Claims: 25
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 2399

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel anti-estrogenic compounds are provided which are useful to treat a variety of disorders, particularly estrogen-dependent disorders. Preferred compounds have a 1,3,5-estratriene nucleus, and are substituted at the C-17 or C-11 position with a molecular moiety which renders the compounds effective to competitively block the binding of estrogen to its receptor. Particularly preferred compounds are 17-desoxy-1,3,5-estratrienes. Therapeutic methods and pharmaceutical compositions are provided as well.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 229634-92-8P 229634-97-3P

(prepn. of novel antiestrogenic steroids)

RN 229634-92-8 USPATFULL

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[3-methoxy-4-(1-piperidinylmethyl)phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229634-97-3 USPATFULL

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[(diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 229634-93-9P 229634-94-0P 229634-95-1P

229634-96-2P 229634-98-4P

(prepn. of novel antiestrogenic steroids)

RN 229634-93-9 USPTAFULL


CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[3-methoxy-4-(1-piperidinylmethyl)phenoxy]-7-methyl-, (7.alpha.)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 229634-92-8

CMF C34 H47 N O3


Absolute stereochemistry.



CM 2

CRN 77-92-9


CMF C6 H8 O7



RN 229634-94-0 USPATFULL

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[2-methoxy-4-[(4-methyl-1-piperazinyl)methyl]phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229634-95-1 USPATFULL

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[2-methoxy-4-(1-pyrrolidinylmethyl)phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229634-96-2 USPATFULL

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[(dimethylamino)methyl]-2-methoxyphenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 229634-98-4 USPATFULL


CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[(diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-, (7.alpha.)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 229634-97-3

CMF C33 H47 N O3


Absolute stereochemistry.



CM 2

CRN 77-92-9

CMF C6 H8 O7



=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 15:53:53 ON 09 JUL 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Jul 2002 VOL 137 ISS 2

FILE LAST UPDATED: 8 Jul 2002 (20020708/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d l14 bib abs hitstr tot retable

L14 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2002 ACS

AN 2002:185695 HCAPLUS

DN 136:232440

TI Preparation of novel anti-estrogenic steroids

IN **Tanabe, Masato; Peters, Richard H.; Chao, Wan-ru;** Jong, Ling

PA USA

SO U.S. Pat. Appl. Publ., 56 pp., Cont.-in-part of U.S. 6,281,205.


CODEN: USXXCO

DT Patent


LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002032180	A1	20020314	US 2001-872825	20010531
	US 6054446	A	20000425	US 1997-998877	19971224
	US 6281205	B1	20010828	US 1998-220408	19981224
PRAI	US 1997-998877	A2	19971224		
	US 1998-220408	A2	19981224		
OS	MARPAT 136:232440				
GI					



I



II

AB Novel antiestrogenic compds., e.g. of formula I [X = hydrocarbon contg. O, S or N, etc.; X1 = H, hydrocarbon contg. O, S or N, etc.; XX1 = heterocycle; Y = C, N; R1 = H, alkyl, halo, etc.; R2 = H, OH, alkyl, alkenyl, aryl, etc.; R3 = H, OH, CN, alkyl, etc.; R4 = H, alkyl; R5 = H, alkoxy, halo, CN, etc.; R6 = H, alkyl, acyl, SO₂NH₂; R7 = H, halo, nitro, CHO, allyl, etc.; R8 = H, OH, etc.; R9 = H, alkyl; R10 = Me, Et], are prepd. which are useful to treat a variety of disorders, particularly estrogen-dependent disorders. Preferred compds. have a 1,3,5-estratriene nucleus, and are substituted at the C-17 or C-11 position with a mol. moiety which renders the compds. effective to competitively block the binding of estrogen to its receptor. Therapeutic methods and pharmaceutical compns. are provided as well. Thus, II citrate salt was prepd. from 7.alpha.-methyl-17.beta.-hydroxyethyl-1,3,5-estratrien-3-ol, vanillin and diethylamine. II citrate salt showed significant growth suppressive activity against MCF-7 tumor in mice at 10 mg/kg/day.


IT 229634-92-8P 229634-97-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of antiestrogenic steroids)

RN 229634-92-8 HCAPLUS

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[3-methoxy-4-(1-piperidinylmethyl)phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229634-97-3 HCAPLUS

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[(diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 229634-93-9P 229634-94-0P 229634-95-1P

229634-96-2P 229634-98-4P 355861-39-1P

355861-40-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of antiestrogenic steroids)

RN 229634-93-9 HCAPLUS


CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[3-methoxy-4-(1-piperidinylmethyl)phenoxy]-7-methyl-, (7.alpha.)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 229634-92-8

CMF C34 H47 N O3


Absolute stereochemistry.



CM 2

CRN 77-92-9


CMF C6 H8 O7



RN 229634-94-0 HCAPLUS

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[2-methoxy-4-[(4-methyl-1-piperazinyl)methyl]phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229634-95-1 HCAPLUS

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[2-methoxy-4-(1-pyrrolidinylmethyl)phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229634-96-2 HCAPLUS

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[(dimethylamino)methyl]-2-methoxyphenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 229634-98-4 HCAPLUS


CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[(diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-, (7.alpha.)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 229634-97-3

CMF C33 H47 N O3


Absolute stereochemistry.



CM 2

CRN 77-92-9


CMF C6 H8 O7



RN 355861-39-1 HCAPLUS



CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[2-(diethylamino)ethoxy]phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 355861-40-4 HCAPLUS

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 7-methyl-21-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, (7.alpha.)- (9CI) (CA INDEX NAME)



AB Novel antiestrogenic compds. are prepd. which are useful to treat a variety of disorders, particularly estrogen-dependent disorders. Preferred compds. have a 1,3,5(10)-estratriene nucleus, and are substituted at the C-17 or C-11 position with a mol. moiety which renders the compds. effective to competitively block the binding of estrogen to its receptor. Particularly preferred compds. are 17-desoxy-1,3,5(10)-estratrienes, e.g. of formula I [R1 = H, alkoxy, halo, CN, etc.; R2 = H, OH, alkyl, etc.; R3 = H, alkyl, acyl, SO2NH2, etc.; R4, R5 = H, alkyl, heterocyclyl; etc.; L = (substituted) five- or six-membered cyclic moiety; m = 1-6; p = 0-6]. Thus, II citrate salt was prepd. and showed strong growth inhibitory activity against MCF-7 human mammary tumor at 10 mg/kg/day. Therapeutic methods and pharmaceutical compns. are provided as well.


IT **229634-92-8P 229634-97-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of antiestrogenic steroids)

RN 229634-92-8 HCAPLUS

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[3-methoxy-4-(1-piperidinylmethyl)phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229634-97-3 HCAPLUS

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[(diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 229634-93-9P 229634-94-0P 229634-95-1P

229634-96-2P 229634-98-4P 355861-39-1P

355861-40-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of antiestrogenic steroids)

RN 229634-93-9 HCAPLUS


CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[3-methoxy-4-(1-piperidinylmethyl)phenoxy]-7-methyl-, (7.alpha.)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 229634-92-8

CMF C34 H47 N O3


Absolute stereochemistry.



CM 2

CRN 77-92-9


CMF C6 H8 O7



RN 229634-94-0 HCAPLUS

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[2-methoxy-4-[(4-methyl-1-piperazinyl)methyl]phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229634-95-1 HCAPLUS

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[2-methoxy-4-(1-pyrrolidinylmethyl)phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229634-96-2 HCAPLUS

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[(dimethylamino)methyl]-2-methoxyphenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 229634-98-4 HCAPLUS


CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[(diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-, (7.alpha.)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 229634-97-3

CMF C33 H47 N O3


Absolute stereochemistry.



CM 2

CRN 77-92-9


CMF C6 H8 O7



RN 355861-39-1 HCAPLUS

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[2-(diethylamino)ethoxy]phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 355861-40-4 HCAPLUS

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 7-methyl-21-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-, (7.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anner	1967			US 3318925	HCAPLUS
Anon	1964			FR 3012 M	
Anon	1965			BE 661288	
Anon	1987			WO 8700175	HCAPLUS
Anon	1998			WO 9807740	HCAPLUS
Benn	1967			US 3318917	HCAPLUS
Benn	1969			US 3448126	HCAPLUS
Bertin	1966			US 3291690	
Blickenstaff	1985	46	889	Steroids	
Bohlmann	1999			US 5866560	HCAPLUS
Bonfils	1997			US 5679668	HCAPLUS
Bonfils	1997			US 5679688	HCAPLUS
Bundy	1993			US 5274089	HCAPLUS
Clark	1994			US 5371078	HCAPLUS
Colton	1954			US 2666769	HCAPLUS
Colton	1970			US 3536703	HCAPLUS
Counsell	1968			US 3405147	HCAPLUS
Hogg	1958			US 2840581	HCAPLUS
Johnson	1997			US 5621123	HCAPLUS
Kim	1996			US 5554603	HCAPLUS
Krubiner	1973			US 3716530	HCAPLUS
Lefebvre	1969			US 3431258	HCAPLUS
Miyairi	1991	56	361	Steroids	HCAPLUS
Nique	1995	20	362	Drugs of the Future	
Peters	1988	32	1642	J Med Chem	
Peters	1989	32	2306	J Med Chem	HCAPLUS
Poirier	1996	16	2537	Bioorganic & Medicin	HCAPLUS
Qian	1988	29	657	J Steroid Biochem	HCAPLUS
Rao	1994	59	621	Steroids	HCAPLUS
Rubio-Poo	1997	7	67	Med Chem Res	HCAPLUS
van de Velde	1995	761	164	Ann N Y Acad Sci	HCAPLUS
van de Velde	1994	42	30	Pathol Biol	
Villani	1966			US 3271428	HCAPLUS
Wakeling	1991	51	3867	Cancer Res	HCAPLUS
Wakeling	1988	31	645	J Steroid Biochem	HCAPLUS
Wakeling	1990	37	771	J Steroid Biochem Mo	HCAPLUS
Young	1975			US 3859365	HCAPLUS
Yuan	1982	39	279	Steroids	HCAPLUS

L14 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2002 ACS
 AN 2001:598005 HCAPLUS
 DN 135:180905
 TI Preparation of antiestrogenic steroids
 IN Peters, Richard H.; Liu, Jyanwei; Johansson, John
 G.; Ryan, Kenneth J.; Chao, Wan-ru; Tanabe,
 Masato
 PA Sri International, USA
 SO PCT Int. Appl., 94 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001058919	A2	20010816	WO 2001-US4266	20010209
	WO 2001058919	A3	20020502		
	W: CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	US 2001039269	A1	20011108	US 2001-780990	20010209
PRAI	US 2000-181738P	P	20000211		
OS	MARPAT 135:180905				
GI					



AB Steroid derivs., such as, [I; R1 = H, alkyl; R2 = H, OH, alkyl, alkoxy, thioalkyl; R3-R5, R7, R9 = H, alkyl; R6 = H, alkyl, acyl, etc.; R8 = H, OH, oxo, alkoxy, acyloxy; R10 = Me, Et; R20 = OH, CH2OH, -(CH2)m-O-p-(subs)C6H4-(CH2)p-1(CO)tNR21R22; m = 0-1; p = 1-7; t = 0-1; R21, R22 = alkyl; R21R22 = cycloalkyl, heterocycloalkyl], or a pharmaceutically acceptable salt thereof, were prep'd to treat a variety of

disorders, particularly estrogen-dependent disorders including prostatic cancer. Thus, 3-hydroxy-7.alpha.-methyl-21-[2'-methoxy-4'-(diethylaminomethyl)phenoxy]-19-norpregna-1,3,5(10)triene citrate ("SR 16234") was prepd. via a multistep synthetic sequence starting from estrone-3-Me ether. SR 16312 (II) exhibited 100% inhibition on androgen-independent human prostate cancer cells, DU145 cells and androgen-dependent PC-3 cells.


IT **354808-46-1P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of antiestrogenic steroids)

RN 354808-46-1 HCAPLUS

CN Benzamide, N,N-diethyl-4-[[[(7.alpha.)-3-hydroxy-7-methyl-19-norpregna-1,3,5(10)-trien-21-yl]oxy]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **354808-47-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of antiestrogenic steroids)

RN 354808-47-2 HCAPLUS


CN Benzamide, N,N-diethyl-4-[[[(7.alpha.)-3-hydroxy-7-methyl-19-norpregna-1,3,5(10)-trien-21-yl]oxy]-3-methoxy-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 354808-46-1

CMF C33 H45 N O4


Absolute stereochemistry.



CM 2

CRN 77-92-9

CMF C6 H8 O7




IT 354758-86-4P 354758-87-5P 354758-98-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. of antiestrogenic steroids)

RN 354758-86-4 HCAPLUS

CN Benzamide, N,N-diethyl-3-methoxy-4-[[(7.alpha.)-7-methyl-3-(1-methylethoxy)-6-oxo-19-norpregna-1,3,5(10)-trien-21-yl]oxy]- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 354758-87-5 HCAPLUS

CN Benzamide, N,N-diethyl-3-methoxy-4-[[3-(1-methylethoxy)-6-oxo-19-norpregna-1,3,5(10)-trien-21-yl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354758-98-8 HCAPLUS


CN Benzamide, N,N-diethyl-3-methoxy-4-[[3-(7.alpha.)-7-methyl-3-[(methylsulfonyl)oxy]-19-norpregna-1,3,5(10)-trien-21-yl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2002 ACS
 AN 1999:460439 HCAPLUS
 DN 131:88084
 TI Preparation of novel antiestrogenic steroids
 IN Tanabe, Masato; Peters, Richard H.; Chao,
 Wan-Ru; Jong, Ling
 PA SRI International, USA
 SO PCT Int. Appl., 142 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9933859	A2	19990708	WO 1998-US27406	19981223
	WO 9933859	A3	19991223		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6054446	A	20000425	US 1997-998877	19971224
	AU 9920104	A1	19990719	AU 1999-20104	19981223
	EP 1056768	A2	20001206	EP 1998-964882	19981223
	R:	DE, FR, GB, IT, NL			
	JP 2001525855	T2	20011211	JP 1999-535172	19981223
	NO 2000003254	A	20000821	NO 2000-3254	20000622
PRAI	US 1997-998877	A	19971224		
	WO 1998-US27406	W	19981223		
OS	MARPAT 131:88084				
GI					



AB Novel anti-estrogenic compds., e.g. I [X = hydrocarbyl including at least one O, N, S; X1 = H, hydrocarbyl including at least one O, N, S; XX1 = heterocycle; Y = C, N; R1 = H, alkyl, halo, alkylidene; R2, R3 = H, OH, alkyl, alkenyl, aryl, etc.; R4 = H, alkyl; R5 = H, alkoxy, halo, CN, CHO, etc.; R6 = H, alkyl, acyl, aroyl, SO₂NH₂; R7 = H, halo, NO₂, CHO, allyl, amino, etc.; R8 = H, OH, etc.; R9 = H, alkyl; R10 = Me, Et], are prepd. which are useful to treat a variety of disorders, particularly estrogen-dependent disorders. Preferred compds. have 1,3,5-estratriene nucleus, and are substituted at the C-17 or C-11 position with a mol. moiety which renders the compds. effective to competitively block the binding of estrogen to its receptor. Particularly preferred compds. are 17-desoxy-1,3,5-estratrienes. Thus, the citrate salt of II was prepd. and was shown to have antitumor activity against tamoxifen-resistant human mammary carcinoma at a dose of 25mg/kg/day.


IT 229634-92-8P 229634-97-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of novel antiestrogenic steroids)

RN 229634-92-8 HCAPLUS

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[3-methoxy-4-(1-piperidinylmethyl)phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229634-97-3 HCAPLUS

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[(diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 229634-93-9P 229634-94-0P 229634-95-1P

229634-96-2P 229634-98-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of novel antiestrogenic steroids)

RN 229634-93-9 HCAPLUS


CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[3-methoxy-4-(1-piperidinylmethyl)phenoxy]-7-methyl-, (7.alpha.)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 229634-92-8

CMF C34 H47 N O3


Absolute stereochemistry.



CM 2

CRN 77-92-9


CMF C6 H8 O7



RN 229634-94-0 HCAPLUS

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[2-methoxy-4-[(4-methyl-1-piperazinyl)methyl]phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229634-95-1 HCAPLUS

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[2-methoxy-4-(1-pyrrolidinylmethyl)phenoxy]-7-methyl-, (7.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229634-96-2 HCAPLUS

CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[(dimethylamino)methyl]-2-methoxyphenoxy]-7-methyl-, (7.alpha.)-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 229634-98-4 HCAPLUS


CN 19-Norpregna-1,3,5(10)-trien-3-ol, 21-[4-[(diethylamino)methyl]-2-methoxyphenoxy]-7-methyl-, (7.alpha.)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 229634-97-3

CMF C33 H47 N O3


Absolute stereochemistry.



CM 2

CRN 77-92-9

CMF C6 H8 O7



=> d his

(FILE 'REGISTRY' ENTERED AT 15:44:48 ON 09 JUL 2002)

DEL HIS

L1 STR

L2 SCR 1992

L3 1 S L1 AND L2

L4 STR L1

L5 2 S L2 AND L4

L6 STR L4

L7 1 S L2 AND L6

L8 116 S L2 AND L6 FUL

SAV L8 QAZI780/A

L9 14 S 4432.3.65/RID AND 46.150.18/RID AND L8

FILE 'HCAOLD' ENTERED AT 15:50:45 ON 09 JUL 2002

L10 0 S L9

FILE 'HCAPLUS' ENTERED AT 15:50:48 ON 09 JUL 2002

L11 4 S L9

L12 4 S L11 AND (PETERS ? OR LIU ? OR JOHANSSON ? OR RYAN ? OR CHAO ?

L13 3 S L11 AND SRI?/PA,CS

L14 4 S L11-L13

FILE 'USPATFULL, USPAT2' ENTERED AT 15:52:38 ON 09 JUL 2002

L15 5 S L9

FILE 'REGISTRY' ENTERED AT 15:53:00 ON 09 JUL 2002

FILE 'USPATFULL, USPAT2' ENTERED AT 15:53:14 ON 09 JUL 2002

FILE 'HCAPLUS' ENTERED AT 15:53:53 ON 09 JUL 2002

(EP(W)594612)

=> s ep 594612/pn
L2 1 EP 594612/PN
(EP594612/PN)

=> d 12

L2 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
AN 1993:32946 CAPLUS
DN 118:32946
TI A substance (.beta.-sitostanol fatty acid esters) for lowering high
cholesterol level in serum and a method for preparing the same
IN Miettinen, Tatu; Vanhanen, Hannu; Wester, Ingmar
PA Raison Margariini Oy, Finland
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9219640	A1	19921112	WO 1991-FI139	19910503
	W: AU, BG, CA, FI, HU, JP, MC, NO, PL, RO, SU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	CA 2102112	AA	19921104	CA 1991-2102112	19910503
	AU 9177505	A1	19921221	AU 1991-77505	19910503
	AU 664827	B2	19951207		
	HU 65318	A2	19940502	HU 1993-3111	19910503
	HU 217625	B	20000328		
	EP 594612	A1	19940504	EP 1991-908435	19910503 <--
	EP 594612	B1	19970806		
	R: AT, BE, DE, DK, FR, GB, IT, LU, NL, SE				
	JP 06506909	T2	19940804	JP 1991-506770	19910503
	PL 166991	B1	19950731	PL 1991-301114	19910503
	AT 156489	E	19970815	AT 1991-908435	19910503
	RU 2095367	C1	19971110	RU 1993-58424	19910503
	NO 9303966	A	19931102	NO 1993-3966	19931102
	FI 98730	B	19970430	FI 1993-4869	19931103
	FI 98730	C	19970811		
	US 5502045	A	19960326	US 1993-140085	19931122
	US 5958913	A	19990928	US 1996-744009	19961105
	FI 9604951	A	19961211	FI 1996-4951	19961211
	US 6174560	B1	20010116	US 1998-190598	19981112
	FI 2001001891	A	20010926	FI 2001-1891	20010926
PRAI	CA 1991-2102112	A	19910503		
	EP 1991-908435	A	19910503		
	WO 1991-FI139		19910503		
	FI 1993-4869	A	19931103		
	US 1993-140085	A2	19931122		
	US 1995-508623	B2	19950728		
	US 1996-744009	A3	19961105		

=>